Literature DB >> 16284558

Evaluation of fractionated radiotherapy and gamma knife radiosurgery in cavernous sinus meningiomas: treatment strategy.

Philipe Metellus1, Jean Regis, Xavier Muracciole, Stephane Fuentes, Henry Dufour, Isabelle Nanni, Oliver Chinot, Pierre-Marie Martin, Francois Grisoli.   

Abstract

OBJECTIVE: To investigate the respective role of fractionated radiotherapy (FR) and gamma knife stereotactic (GKS) radiosurgery in cavernous sinus meningioma (CSM) treatment.
METHODS: The authors report the long-term follow-up of two populations of patients harboring CSMs treated either by FR (Group I, 38 patients) or GKS radiosurgery (Group II, 36 patients). There were 31 females with a mean age of 53 years in Group I and 29 females with a mean age of 51.2 years in Group II. In 20 patients (Group I) and 13 patients (Group II), FR and GKS radiosurgery were performed as an adjuvant treatment. In 18 patients (Group I) and in 23 patients (Group II), FR and GKS radiosurgery were performed as first line treatment. In our early experience with GKS radiosurgery (1992, date of gamma knife availability in the department), patients with tumors greater than 3 cm, showing close relationship with the optic apparatus (<3 mm) or skull base dural spreading, were treated by FR. Secondarily, with the advent of new devices and our growing experience, these criteria have evolved.
RESULTS: The median follow-up period was 88.6 months (range, 42-168 mo) for Group I and 63.6 months (range, 48-92 mo) for Group II. According to Sekhar's classification, 26 (68.4%) patients were Grade III to IV in Group I and 10 (27.8%) patients in Group II (P < 0.05); 23 (60.5%) patients had extensive lesions in Group I and 7 (19.4%) patients in Group II (P < 0.05). Mean tumor volume was 13.5 cm in Group I and 5.2 cm in Group II (P < 0.05). Actuarial progression-free survival was 94.7% and 94.4% in Group I and II, respectively. Clinically, improvement was seen for 24 (63.2%) patients in Group I and for 21 (53.8%) patients in Group II (P > 0.05). Radiologically, 11 (29%, Group I) patients and 19 (Group II, 52.7%) patients showed tumor shrinkage (P = 0.04). Transient morbidity was 10.5% in Group I and 2.8% in Group II. Permanent morbidity was 2.6% in Group I and 0% in Group II.
CONCLUSION: FR and GKS radiosurgery are safe and efficient techniques in treatment of CSMs, affording comparable satisfactory long-term tumor control. However, GKS radiosurgery provides better radiological response, is far more convenient, and fits into most patients lives much better than FR. Therefore, in the authors' opinion, GKS radiosurgery should be advocated in first intention for patients with CSMs, whereas conventional radiotherapy should be reserved for cases that are not amenable to this technique, thus making these two therapeutic modalities not alternative but complementary tools in CS meningioma treatment strategy.

Entities:  

Mesh:

Year:  2005        PMID: 16284558     DOI: 10.1227/01.neu.0000179924.76551.cd

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  25 in total

1.  Clinical outcomes of perioptic tumors treated with hypofractionated stereotactic radiotherapy using CyberKnife® stereotactic radiosurgery.

Authors:  Putipun Puataweepong; Mantana Dhanachai; Ake Hansasuta; Somjai Dangprasert; Chomporn Sitathanee; Rawee Ruangkanchanasetr; Pornpan Yongvithisatid
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

2.  High symptom improvement and local tumor control using stereotactic radiotherapy when given early after diagnosis of meningioma. A multicentre study.

Authors:  I Compter; K Zaugg; R M A Houben; J T A Dings; G Bosmans; C Buescher; M M H M E Anten; B G Baumert
Journal:  Strahlenther Onkol       Date:  2012-09-09       Impact factor: 3.621

3.  TomoTherapy, Gamma Knife, and CyberKnife Therapies for Patients with Tumours of the Lung, Central Nervous System, or Intra-abdomen: A Systematic Review of Clinical Effectiveness and Cost-Effectiveness.

Authors: 
Journal:  CADTH Technol Overv       Date:  2010-09-01

Review 4.  Radiotherapy for prolactin-secreting pituitary tumors.

Authors:  Lawrence J Sheplan Olsen; Lizbeth Robles Irizarry; Samuel T Chao; Robert J Weil; Amir H Hamrahian; Betul Hatipoglu; John H Suh
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

5.  Quantitative analysis of tumor volume reduction after three-dimensional conformal radiation therapy for intracranial meningiomas.

Authors:  Nam Kwon Lee; Chul Yong Kim; Won Sup Yoon; Yong Gu Chung; Nam Joon Lee
Journal:  J Neurooncol       Date:  2014-10-08       Impact factor: 4.130

6.  Treatment policy for petroclival meningioma based on tumor size: aiming radical removal in small tumors for obtaining cure without morbidity.

Authors:  Iwao Yamakami; Yoshinori Higuchi; Kentaro Horiguchi; Naokatsu Saeki
Journal:  Neurosurg Rev       Date:  2011-02-22       Impact factor: 3.042

7.  Radiosurgical decompression for benign perioptic tumors causing compressive cranial neuropathies: a feasible alternative to microsurgery?

Authors:  Eun Jung Lee; Young Hyun Cho; KyoungJun Yoon; Byungchul Cho; Eun Suk Park; Chang Jin Kim; Sung Woo Roh
Journal:  J Neurooncol       Date:  2016-09-06       Impact factor: 4.130

8.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

9.  A prospective study of cavernous sinus surgery for meningiomas and resultant common ophthalmic complications (an American Ophthalmological Society thesis).

Authors:  Steven Newman
Journal:  Trans Am Ophthalmol Soc       Date:  2007

Review 10.  Radiotherapy and radiosurgery for benign skull base meningiomas.

Authors:  Giuseppe Minniti; Maurizio Amichetti; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2009-10-14       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.